Advertisement
LENZ vs MIST
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LENZ is a Buy and MIST is a Hold.
LENZ's RSI Oscillator ascending out of oversold territory
The RSI Indicator for LENZ moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 25 of the 29 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 65 cases where LENZ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on LENZ as a result. In 74 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for LENZ just turned positive on October 09, 2026. Looking at past instances where LENZ's MACD turned positive, the stock continued to rise in 45 of 55 cases over the following month. The odds of a continued upward trend are 82%.
Following a +10.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where LENZ advanced for three days, in 234 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
LENZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LENZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for LENZ entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.496) is normal, around the industry mean (2.904). P/E Ratio (-0.838) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (5.903) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. LENZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LENZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MIST's RSI Oscillator ascending out of oversold territory
The RSI Indicator for MIST moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 27 of the 31 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 57 cases where MIST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on MIST as a result. In 69 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for MIST just turned positive on October 27, 2026. Looking at past instances where MIST's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
Following a +7.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.279) is normal, around the industry mean (2.904). P/E Ratio (-1.188) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MIST | ||
|---|---|---|
OUTLOOK RATING 1..100 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 82 | |
P/E GROWTH RATING 1..100 | 15 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| LENZ | MIST | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 86% |
| Advances ODDS (%) | 8 days ago 83% | 2 days ago 84% |
| Declines ODDS (%) | 11 days ago 85% | 4 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 72% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LENZ’s FA Score shows that 1 FA rating(s) are green while MIST’s FA Score has 1 green FA rating(s).
- LENZ’s FA Score: 1 green, 4 red.
- MIST’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LENZ’s TA Score shows that 6 TA indicator(s) are bullish while MIST’s TA Score has 6 bullish TA indicator(s).
- LENZ’s TA Score: 6 bullish, 2 bearish.
- MIST’s TA Score: 6 bullish, 2 bearish.
Price Growth
LENZ (@Biotechnology) experienced а +7.79% price change this week, while MIST (@Biotechnology) price change was +1.99% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.18%. For the same industry, the average monthly price growth was -13.79%, and the average quarterly price growth was -20.74%.
Reported Earning Dates
LENZ is expected to report earnings on Mar 24, 2027.
MIST is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-8.18% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RXL | 73.67 | 4.35 | +6.28% |
| ProShares Ultra Health Care (RXL) | |||
| PCPP | 27.90 | 0.60 | +2.21% |
| Porter & Company Porter Portfolio Index ETF (PCPP) | |||
| PXH | 28.25 | 0.48 | +1.73% |
| Invesco RAFI Emerging Markets ETF (PXH) | |||
| EELV | 28.21 | 0.36 | +1.29% |
| Invesco S&P Emerging Markets Low Volatility ETF (EELV) | |||
| EMSC | 25.08 | N/A | N/A |
| Sophus Capital Emerging Market Small Cap ETF (EMSC) | |||